Casdin Capital
Latest statistics and disclosures from Casdin Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, LAB, BLFS, SRPT, RLAY, and represent 52.81% of Casdin Capital's stock portfolio.
- Added to shares of these 10 stocks: LAB (+$165M), ALNY (+$24M), RNA (+$23M), VCYT (+$19M), EXAS (+$16M), NTLA (+$13M), SRPT (+$8.1M), BEAM, TSVT, Kyverna Therapeutics.
- Started 3 new stock positions in VCYT, DNA, Kyverna Therapeutics.
- Reduced shares in these 7 stocks: Somalogic (-$32M), ILMN (-$12M), PLRX (-$8.6M), FATE (-$7.7M), FDMT (-$7.4M), RVMD, LIANY.
- Sold out of its positions in FATE, LIANY, Somalogic.
- Casdin Capital was a net buyer of stock by $214M.
- Casdin Capital has $1.3B in assets under management (AUM), dropping by 32.04%.
- Central Index Key (CIK): 0001534261
Tip: Access up to 7 years of quarterly data
Positions held by Casdin Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Casdin Capital
Casdin Capital holds 36 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | 13.5 | $181M | 5.6M | 32.23 |
|
|
| D Fluidigm Corp Del (LAB) | 12.5 | $168M | +5058% | 62M | 2.71 |
|
| Biolife Solutions Com New (BLFS) | 12.0 | $162M | 8.7M | 18.55 |
|
|
| Sarepta Therapeutics (SRPT) | 10.3 | $138M | +6% | 1.1M | 129.46 |
|
| Relay Therapeutics (RLAY) | 4.6 | $62M | 7.4M | 8.30 |
|
|
| Alnylam Pharmaceuticals (ALNY) | 4.0 | $54M | +83% | 358k | 149.45 |
|
| Avidity Biosciences Ord (RNA) | 4.0 | $53M | +77% | 2.1M | 25.52 |
|
| Intellia Therapeutics (NTLA) | 3.9 | $53M | +32% | 1.9M | 27.51 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 3.6 | $48M | 1.1M | 42.86 |
|
|
| EXACT Sciences Corporation (EXAS) | 3.3 | $45M | +54% | 650k | 69.06 |
|
| Verve Therapeutics (VERV) | 3.0 | $41M | 3.1M | 13.28 |
|
|
| Tenaya Therapeutics (TNYA) | 2.6 | $35M | +5% | 6.7M | 5.23 |
|
| Illumina (ILMN) | 2.5 | $34M | -26% | 248k | 137.32 |
|
| Blueprint Medicines (BPMC) | 2.3 | $31M | 326k | 94.86 |
|
|
| Genedx Holdings Corp Com Cl A (WGS) | 2.1 | $29M | 3.1M | 9.13 |
|
|
| Neurogene (NGNE) | 2.0 | $27M | 525k | 50.90 |
|
|
| Denali Therapeutics (DNLI) | 2.0 | $27M | 1.3M | 20.52 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 1.9 | $26M | -22% | 800k | 31.86 |
|
| Beam Therapeutics (BEAM) | 1.7 | $22M | +27% | 675k | 33.04 |
|
| Veracyte (VCYT) | 1.4 | $19M | NEW | 858k | 22.16 |
|
| Pliant Therapeutics (PLRX) | 1.1 | $15M | -36% | 1.0M | 14.90 |
|
| Century Therapeutics (IPSC) | 1.0 | $13M | 3.2M | 4.18 |
|
|
| 2seventy Bio Common Stock (TSVT) | 0.8 | $11M | +69% | 2.0M | 5.35 |
|
| Abcellera Biologics (ABCL) | 0.8 | $11M | 2.4M | 4.53 |
|
|
| Tango Therapeutics (TNGX) | 0.7 | $9.4M | 1.2M | 7.94 |
|
|
| Codexis (CDXS) | 0.5 | $7.0M | 2.0M | 3.49 |
|
|
| Absci Corp (ABSI) | 0.4 | $5.5M | 973k | 5.68 |
|
|
| Pacific Biosciences of California (PACB) | 0.3 | $3.9M | 1.0M | 3.75 |
|
|
| Kyverna Therapeutics | 0.3 | $3.7M | NEW | 150k | 24.84 |
|
| Monte Rosa Therapeutics (GLUE) | 0.3 | $3.6M | 511k | 7.05 |
|
|
| Syndax Pharmaceuticals (SNDX) | 0.3 | $3.6M | 150k | 23.80 |
|
|
| Prime Medicine (PRME) | 0.2 | $2.6M | 367k | 7.00 |
|
|
| Ginkgo Bioworks Holdings Cl A Shs (DNA) | 0.1 | $1.7M | NEW | 1.5M | 1.16 |
|
| Exscientia Ads (EXAI) | 0.1 | $1.2M | 214k | 5.72 |
|
|
| Singular Genomics Systems In (OMIC) | 0.1 | $681k | 1.3M | 0.51 |
|
|
| Kronos Bio (KRON) | 0.0 | $161k | 124k | 1.30 |
|
Past Filings by Casdin Capital
SEC 13F filings are viewable for Casdin Capital going back to 2015
- Casdin Capital 2024 Q1 filed May 15, 2024
- Casdin Capital 2023 Q4 filed Feb. 14, 2024
- Casdin Capital 2023 Q3 filed Nov. 14, 2023
- Casdin Capital 2023 Q2 filed Aug. 14, 2023
- Casdin Capital 2023 Q1 filed May 15, 2023
- Casdin Capital 2022 Q4 filed Feb. 14, 2023
- Casdin Capital 2022 Q3 filed Nov. 14, 2022
- Casdin Capital 2022 Q2 filed Aug. 15, 2022
- Casdin Capital 2022 Q1 filed May 16, 2022
- Casdin Capital 2021 Q4 filed Feb. 14, 2022
- Casdin Capital 2021 Q3 filed Nov. 15, 2021
- Casdin Capital 2021 Q2 filed Aug. 16, 2021
- Casdin Capital 2021 Q1 filed May 17, 2021
- Casdin Capital 2020 Q4 filed Feb. 16, 2021
- Casdin Capital 2020 Q3 filed Nov. 16, 2020
- Casdin Capital 2020 Q2 filed Aug. 14, 2020